| . | All . | Up to 2010 . | After 2010 . | P . |
|---|---|---|---|---|
| No. (%) | 118 (100) | 42 (35.6) | 76 (64.4) | |
| BMI median (IQR) | 29.2 (4.9) | 28.6 (4.4) | 29.5 (5.1) | .54 |
| Diabetes, n (%) | 40 (33.9) | 13 (31.0) | 27 (35.3) | .38 |
| Hypertension, n (%) | 91 (77.1) | 29 (69.1) | 62 (81.6) | .09 |
| Dyslipidemia, n (%) | 44 (37.9) | 8 (19.1) | 36 (47.4) | .01 |
| Arthropathy, n (%) | 54 (45.7) | 23 (56.1) | 31 (40.8) | .08 |
| Polyposis, n (%)a | 22 (19.5) | 5 (12.8) | 17 (23.0) | .15 |
| OSAS, n (%)b | 30 (25.8) | 5 (12.8) | 25 (32.9) | .03 |
| Goiter, n (%) | 38 (32.2) | 12 (28.6) | 26 (34.2) | .34 |
| Hypopituitarism, n (%) | 4 (3.4) | 0 | 4 (5.3) | — |
| CVD, n (%) | 17 (14.4) | 3 (7.1) | 14 (18.4) | .08 |
| Cancer, n (%) | 11 (9.3) | 5 (11.9) | 6 (7.9) | .34 |
| Follow-up, mo, median (IQR) | 103.5 (72.7) | 169.4 (100.3) | 59.6 (58.1) | .01 |
| . | All . | Up to 2010 . | After 2010 . | P . |
|---|---|---|---|---|
| No. (%) | 118 (100) | 42 (35.6) | 76 (64.4) | |
| BMI median (IQR) | 29.2 (4.9) | 28.6 (4.4) | 29.5 (5.1) | .54 |
| Diabetes, n (%) | 40 (33.9) | 13 (31.0) | 27 (35.3) | .38 |
| Hypertension, n (%) | 91 (77.1) | 29 (69.1) | 62 (81.6) | .09 |
| Dyslipidemia, n (%) | 44 (37.9) | 8 (19.1) | 36 (47.4) | .01 |
| Arthropathy, n (%) | 54 (45.7) | 23 (56.1) | 31 (40.8) | .08 |
| Polyposis, n (%)a | 22 (19.5) | 5 (12.8) | 17 (23.0) | .15 |
| OSAS, n (%)b | 30 (25.8) | 5 (12.8) | 25 (32.9) | .03 |
| Goiter, n (%) | 38 (32.2) | 12 (28.6) | 26 (34.2) | .34 |
| Hypopituitarism, n (%) | 4 (3.4) | 0 | 4 (5.3) | — |
| CVD, n (%) | 17 (14.4) | 3 (7.1) | 14 (18.4) | .08 |
| Cancer, n (%) | 11 (9.3) | 5 (11.9) | 6 (7.9) | .34 |
| Follow-up, mo, median (IQR) | 103.5 (72.7) | 169.4 (100.3) | 59.6 (58.1) | .01 |
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; IQR, interquartile range; OSAS, obstructive sleep apnea syndrome.
Reported in 113 patients.
Reported in 116 patients.
| . | All . | Up to 2010 . | After 2010 . | P . |
|---|---|---|---|---|
| No. (%) | 118 (100) | 42 (35.6) | 76 (64.4) | |
| BMI median (IQR) | 29.2 (4.9) | 28.6 (4.4) | 29.5 (5.1) | .54 |
| Diabetes, n (%) | 40 (33.9) | 13 (31.0) | 27 (35.3) | .38 |
| Hypertension, n (%) | 91 (77.1) | 29 (69.1) | 62 (81.6) | .09 |
| Dyslipidemia, n (%) | 44 (37.9) | 8 (19.1) | 36 (47.4) | .01 |
| Arthropathy, n (%) | 54 (45.7) | 23 (56.1) | 31 (40.8) | .08 |
| Polyposis, n (%)a | 22 (19.5) | 5 (12.8) | 17 (23.0) | .15 |
| OSAS, n (%)b | 30 (25.8) | 5 (12.8) | 25 (32.9) | .03 |
| Goiter, n (%) | 38 (32.2) | 12 (28.6) | 26 (34.2) | .34 |
| Hypopituitarism, n (%) | 4 (3.4) | 0 | 4 (5.3) | — |
| CVD, n (%) | 17 (14.4) | 3 (7.1) | 14 (18.4) | .08 |
| Cancer, n (%) | 11 (9.3) | 5 (11.9) | 6 (7.9) | .34 |
| Follow-up, mo, median (IQR) | 103.5 (72.7) | 169.4 (100.3) | 59.6 (58.1) | .01 |
| . | All . | Up to 2010 . | After 2010 . | P . |
|---|---|---|---|---|
| No. (%) | 118 (100) | 42 (35.6) | 76 (64.4) | |
| BMI median (IQR) | 29.2 (4.9) | 28.6 (4.4) | 29.5 (5.1) | .54 |
| Diabetes, n (%) | 40 (33.9) | 13 (31.0) | 27 (35.3) | .38 |
| Hypertension, n (%) | 91 (77.1) | 29 (69.1) | 62 (81.6) | .09 |
| Dyslipidemia, n (%) | 44 (37.9) | 8 (19.1) | 36 (47.4) | .01 |
| Arthropathy, n (%) | 54 (45.7) | 23 (56.1) | 31 (40.8) | .08 |
| Polyposis, n (%)a | 22 (19.5) | 5 (12.8) | 17 (23.0) | .15 |
| OSAS, n (%)b | 30 (25.8) | 5 (12.8) | 25 (32.9) | .03 |
| Goiter, n (%) | 38 (32.2) | 12 (28.6) | 26 (34.2) | .34 |
| Hypopituitarism, n (%) | 4 (3.4) | 0 | 4 (5.3) | — |
| CVD, n (%) | 17 (14.4) | 3 (7.1) | 14 (18.4) | .08 |
| Cancer, n (%) | 11 (9.3) | 5 (11.9) | 6 (7.9) | .34 |
| Follow-up, mo, median (IQR) | 103.5 (72.7) | 169.4 (100.3) | 59.6 (58.1) | .01 |
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; IQR, interquartile range; OSAS, obstructive sleep apnea syndrome.
Reported in 113 patients.
Reported in 116 patients.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
